WFH Gene Therapy Registry to Track Long Term Safety and Efficacy
Speakers: Glenn Pierce, MD, PhD, Vice President, Medical, WFH and Donna Coffin, MSc, Head of Research, WFH
Did you miss the April 21st Wednesday Webinar? If so you can view it here and join Glenn Pierce, MD, PhD, Vice President, Medical, WFH and Donna Coffin, MSc, Head of Research, WFH as they detail the goals and objectives of the World Federation of Hemophilia's Gene Therapy Registry to Track Long Term Safety and Efficacy. The registry aims to collect long-term data on all people with hemophilia who receive gene therapy, worldwide. The primary objective of the registry is to determine the long-term safety of FVIII and FIX gene therapies in people with hemophilia, and also to determine the long-term efficacy and durability of FVIII and FIX gene therapies in people with hemophilia, and to assess the long-term quality of life (EQ-5D-5L) and burden of disease (PROBE) post gene therapy infusion. This webinar is for hematologists, researchers, and others interested in gene therapy research.